Literature DB >> 29222289

What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Shaina M Willen1, Mark T Gladwin2.   

Abstract

Patient case: An 18-year-old male patient with homozygous hemoglobin SS disease was evaluated for progressive dyspnea and elevated tricuspid regurgitant jet velocity (TRV) on echocardiography. The patient's case is described in detail in Lancet1 He had been treated with regular transfusions since childhood for stroke, had rare episodes of vaso-occlusive pain episodes, and did not take narcotic pain medications. He presented with progressive severe dyspnea on exertion and lower extremity edema. His laboratory tests were notable for a total hemoglobin level of 11.8 g/dL and hemoglobin S levels <30% but with 18% reticulocytes and elevated markers of hemolysis, such as high plasma levels of lactate dehydrogenase, aspartate amino transferase, and indirect bilirubin. The computed tomography scan of his chest in Figure 1A-B shows a large pulmonary artery, which has a greater diameter than his aorta, and a mosaic perfusion pattern, typical for severe pulmonary arterial hypertension. His Doppler echocardiographic study (Figure 1C) showed an unusually high TRV of 5.93 m/s, consistent with a calculated pulmonary artery systolic pressure of >140 mm Hg (4 times the TRV squared = 4V2). Additional images in Figure 1D show a dilated right ventricle and right atrium with a compressed left ventricle. The patient's right heart catheterization revealed a pulmonary artery systolic pressure of 147 mm Hg and diastolic pressure of 49 mm Hg; note that the normal values are ∼25/10 mm Hg.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29222289      PMCID: PMC6142565          DOI: 10.1182/asheducation-2017.1.431

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  17 in total

1.  Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease.

Authors:  Robert I Liem; Mary A Nevin; Adrienne Prestridge; Luciana T Young; Alexis A Thompson
Journal:  Pediatr Pulmonol       Date:  2009-03

2.  Pulmonary hypertension in patients with sickle cell disease: a longitudinal study.

Authors:  Kenneth I Ataga; Charity G Moore; Susan Jones; Oludamilola Olajide; Dell Strayhorn; Alan Hinderliter; Eugene P Orringer
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

3.  Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation.

Authors:  C Pittman; M M Hsieh; W Coles; J F Tisdale; N A Weir; C D Fitzhugh
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

4.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

Review 5.  Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review.

Authors:  Melissa C Caughey; Charles Poole; Kenneth I Ataga; Alan L Hinderliter
Journal:  Br J Haematol       Date:  2015-04-09       Impact factor: 6.998

6.  Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.

Authors:  Victor R Gordeuk; Caterina P Minniti; Mehdi Nouraie; Andrew D Campbell; Sohail R Rana; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory Ensing; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

7.  Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Authors:  Roberto F Machado; Robyn J Barst; Nancy A Yovetich; Kathryn L Hassell; Gregory J Kato; Victor R Gordeuk; J Simon R Gibbs; Jane A Little; Dean E Schraufnagel; Lakshmanan Krishnamurti; Reda E Girgis; Claudia R Morris; Erika B Rosenzweig; David B Badesch; Sophie Lanzkron; Onyinye Onyekwere; Oswaldo L Castro; Vandana Sachdev; Myron A Waclawiw; Rob Woolson; Jonathan C Goldsmith; Mark T Gladwin
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

8.  Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Public Health Rep       Date:  2013 Mar-Apr       Impact factor: 2.792

9.  Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought?

Authors:  Camden Hebson; Tamara New; Elizabeth Record; Matthew Oster; Alexandra Ehrlich; William Border; Angelica James-Herry; Usama Kanaan
Journal:  J Pediatr Hematol Oncol       Date:  2015-03       Impact factor: 1.289

10.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Authors:  Oswaldo Castro; Mohammed Hoque; Bernice D Brown
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  2 in total

1.  Exercise-induced changes of vital signs in adults with sickle cell disease.

Authors:  Solomon Johnson; Victor R Gordeuk; Roberto Machado; J Simon R Gibbs; Mariana Hildesheim; Jane A Little; Gregory J Kato; Mark T Gladwin; Mehdi Nouraie
Journal:  Am J Hematol       Date:  2021-10-20       Impact factor: 10.047

2.  Sickle cell disease and ventricular myocardial strain: A systematic review.

Authors:  Nicholas S Whipple; Vijaya M Joshi; Ronak J Naik; Tisha Mentnech; Mary M McFarland; Vikki G Nolan; Jane S Hankins
Journal:  Pediatr Blood Cancer       Date:  2021-03-19       Impact factor: 3.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.